15:55 Dec 20
Valiant Laboratories Ltd.
Sector Pharmaceuticals & Biotechnology
Industry Pharmaceuticals
Valiant Laboratories Ltd.
Industry Pharmaceuticals
15:55 Dec 20
Quality
57/100
High Financial Strength
Valuation
18/100
Expensive Valuation
Technical
38/100
Technically Neutral
Strength
4
Weakness
5
Opportunity
0
Threats
0
0.13 %
ROE %
0.09 %
ROA %
-2.30
EPS
54.51
BVPS
0.17 %
Net Profit Margin
| Mar 2023 | Mar 2024 | TTM 2024 | ||
|---|---|---|---|---|
| Net Sales | 333.91 | 182.06 | 111.47 | |
| Operating Expenses + | 298.83 | 190.46 | 131.43 | |
| Raw Material | 277.56 | 169.39 | 104.9 | |
| Increase Decrease in Cost | -0.24 | -1.14 | 5.83 | |
| Other Manufacturing Expense | 0 | 0 | 0 | |
| Employee Cost | 4.61 | 4.31 | 4.62 | |
| Miscellaneous Expenses | 17.46 | 17.9 | 16.08 | |
| Operating Profit | 35.08 | -8.4 | -19.96 | |
| Other Income | 4.86 | 9.68 | 10.45 | |
| Depreciation | 1.56 | 1.97 | 2.06 | |
| Interest | 0.25 | 0.08 | 0.1 | |
| Profit before tax and exceptio.. | 38.14 | -0.77 | -11.67 | |
| Exceptional Items | 0 | 0 | 0 | |
| PBT | 38.14 | -0.77 | -11.67 | |
| Provision for Taxation | 9.14 | -1.09 | -1.69 | |
| Net Profit | 29 | 0.32 | -9.99 | |
| NET Profit after MI | 29 | 0.32 | -9.99 | |
| EPS | 8.91 | 0.13 | -2.35 | |
| Operating Profit Margin (%) | 10.51 | -4.61 | -17.91 | |
| Net Profit Margin (%) | 8.69 | 0.18 | -8.96 |
ShareHolding
Promoter
FII
Public
Mutual Funds
Other Institutions
All Data in Percentage (%)
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| Promoter | 74.90 | 74.90 | 74.90 | 74.90 |
| FII | 0.00 | 1.90 | 3.50 | 7.10 |
| MF | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 25.10 | 23.20 | 21.60 | 17.50 |
| Others | 0.00 | 0.00 | 0.00 | 0.10 |
| Others | 0.00 | 0.00 | 0.00 | 0.40 |
| Shareholder | Shares | Holding % |
|---|
Download Our App On:
